Lidia Wydeheft

Lidia Wydeheft

Auto-generated profile, based on publicly available information

Lidia Wydeheft


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
MGMirosław Andrzej Gozdek
Mirosław Andrzej Gozdek
ŁKŁukasz Kuźma
Łukasz Kuźma
EDEmil Julian Dąbrowski
Emil Julian Dąbrowski
MJMichał Janiak
Michał Janiak
MPMartyna Pietrzak
Martyna Pietrzak
Mariusz KowalewskiMariusz Kowalewski
Mariusz Kowalewski
Background: Transcatheter aortic valve implantation (TAVI) has become a broadly acceptable alternative to AV surgery in patients with aortic stenosis (AS). New valve designs are becoming available to address the shortcomings of their predecessors and improve clinical outcomes. Methods: A systematic review and meta-analysis was carried out to compare Medtronic’s Evolut PRO, a new valve, with the previous Evolut R design. Procedural, functional and clinical endpoints according to the VARC-2 criteria were assessed. Results: Eleven observational studies involving N = 12,363 patients were included. Evolut PRO patients differed regarding age (p < 0.001), sex (p < 0.001) and STS–PROM estimated risk. There was no difference between the two devices in terms of TAVI-related early complications and clinical endpoints. A 35% reduction of the risk of moderate-to-severe paravalvular leak (PVL) favoring the Evolut PRO was observed (RR 0.66, 95%CI, [0.52, 0.86] p = 0.002; I2 = 0%). Similarly, Evolut PRO-treated patients demonstrated a reduction of over 35% in the risk of serious bleeding as compared with the Evolut R (RR 0.63, 95%CI, [0.41, 0.96]; p = 0.03; I2 = 39%), without differences in major vascular complications. Conclusions: The evidence shows good short-term outcomes of both the Evolut PRO and Evolut R prostheses, with no differences in clinical and procedural endpoints. The Evolut PRO was associated with a lower rate of moderate-to-severe PVL and major bleeding.

24 January 2026 in Quality in Sport
Verified
Journal Article
Open access
PHPaulina Halik
Paulina Halik
JJJustyna Jusiak
Justyna Jusiak
LWLidia Wydeheft
Lidia Wydeheft
PMPaulina Malon
Paulina Malon
JLJakub Lewiński
Jakub Lewiński
KKKornelia Kędziora-Kornatowska
Kornelia Kędziora-Kornatowska
Introduction:Falls among older adults are a major global public health problem and a leading cause of injury, disability and mortality in individuals aged 65 years and older. With population aging, the incidence and burden of falls are expected to increase. Falls result from complex interactions between intrinsic age-related changes and extrinsic environmental factors, making them a core geriatric syndrome requiring comprehensive management.Aim:This review aimed to summarize current evidence on the epidemiology, determinants, consequences, and prevention strategies for falls in older adults.Materials and Methods:A narrative review was conducted using PubMed, Scopus, and Web of Science databases. Peer-reviewed articles, meta-analyses, and clinical guidelines published between 2018 and 2025 were included.Results:Approximately one-third of community-dwelling adults aged ≥65 experience at least one fall annually, with higher rates among those aged ≥80 and residents of long-term care facilities. Major risk factors include advanced age, prior falls, gait and balance impairment, muscle weakness, frailty, multimorbidity, polypharmacy, visual and cognitive impairment, and environmental hazards. Falls often lead to fractures, head injuries, functional decline, psychological consequences such as fear of falling, and increased healthcare utilization. Discussion:The findings confirm the multifactorial nature of falls and the cumulative impact of modifiable and non-modifiable risk factors. Psychological consequences, particularly fear of falling, contribute to recurrent falls and progressive functional decline. Conclusions:Falls in older adults represent a complex geriatric syndrome with substantial clinical and socioeconomic consequences. Integrated, multifactorial prevention programs based on comprehensive geriatric assessment are essential to reduce fall risk, maintain independence, and mitigate healthcare system burden.

30 June 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PGPaweł Gordon
Paweł Gordon
MJMichał Janiak
Michał Janiak
Katarzyna Mądra-GackowskaKatarzyna Mądra-Gackowska
Katarzyna Mądra-Gackowska
LWLidia Wydeheft
Lidia Wydeheft
IHIga Hołyńska-Iwan
Iga Hołyńska-Iwan
Marcin GackowskiMarcin Gackowski
Marcin Gackowski
Factor Xa (FXa) remains a clinically validated and chemically tractable anticoagulant target despite the therapeutic role of direct oral FXa inhibitors. Contemporary FXa inhibitor literature, however, is heterogeneous in scaffold design, endpoint reporting, assay consistency, translational depth, and suitability for computer-aided drug design (CADD). This review evaluates published series of small-molecule FXa inhibitors through a framework that combines translational structure–activity relationships (SARs), assay-aware data quality, and QSAR-readiness. A structured narrative synthesis focused mainly on post-2014 studies reporting discrete small-molecule or semisynthetic FXa inhibitors. Eligible series were classified as fully synthetic or natural-product-derived/semisynthetic chemotypes, and extraction covered scaffold architecture, potency endpoints, assay context, selectivity, clotting or antithrombotic readouts, PK/ADME, structural clarity, translational context, and extraction confidence. QSAR-readiness was assessed using analog density, congenericity, endpoint quality, assay comparability, activity range, structural interpretability, and curation burden. Fully synthetic chemotypes, particularly anthranilamide-derived and related scaffolds, provided the most coherent and modellable FXa datasets, whereas natural-product-derived and semisynthetic series expanded structural diversity. Many exploratory series, however, were limited by small analog sets, heterogeneous endpoints, incomplete translational characterization, narrow activity ranges, or higher curation burden. The practical value of published FXa inhibitor series, therefore, depends not only on potency but also on whether chemical and biological information can be reconstructed with confidence for reproducible SAR interpretation, local QSAR modeling, AI/ML-enabled CADD reuse, and clinical benchmark-aware prioritization. The QSAR-readiness framework is a critical triage tool, not a substitute for formal validation, distinguishing datasets suitable for curated local modeling from those better suited to qualitative SAR, scaffold inspiration, or translational hypotheses.

26 April 2022 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
AWAleksandra Wijata
Aleksandra Wijata
LWLidia Wydeheft
Lidia Wydeheft
MJMichał Janiak
Michał Janiak
KFKamila Fronc
Kamila Fronc
KKKornelia Kędziora-Kornatowska
Kornelia Kędziora-Kornatowska
Introduction: Obstructive Sleep Apnea is a disease entity that affects many aspects of life, but is often overlooked and underdiagnosed. OSA is defined as episodes of apnea-hypopnea that disturbs not only sleep, but also daytime functioning. Symptoms can be divided into night symptoms (not breathing, snoring, gasping, fragmented sleep) and daytime symptoms (fatigue, low concentration, morning headaches, decreased libido). Moreover, OSA through many mechanisms affects the cardiovascular system and leads to its dysfunction. Purpose: The aim of this study is to draw attention to the often underdiagnosed disease entity, which is OSA, which, if left untreated, may lead to serious complications. Material and methods: In 2022, the PubMed and Google Scholar databases were searched using the following keywords: OSA, apnea, cardiovascular disorders, arrhythmias and heart disease. Works in English with the most recent data have been selected. Summary: OSA is strongly associated with cardiovascular disorders, moreover, in both cases, we find similar risk factors for these disorders. A correlation has been demonstrated between OSA and atrial fibrillation, hypertension, and arrhythmias. On the other hand, OSA is still underdiagnosed and more research is needed to understand the correlation between these diseases.

31 December 2025 in Quality in Sport
Verified
Journal Article
Open access
LWLidia Wydeheft
Lidia Wydeheft
PMPaulina Malon
Paulina Malon
ABAnna Bych
Anna Bych
PHPaulina Halik
Paulina Halik
JJJustyna Jusiak
Justyna Jusiak
KKKornelia Kędziora-Kornatowska
Kornelia Kędziora-Kornatowska
IntroductionThe aging population has increased the number of older adults undergoing elective surgery, making safe, individualized general anesthesia essential. Age-related physiological changes—such as reduced cardiac, pulmonary, hepatic, and renal reserve, multimorbidity, frailty, and altered body composition—affect drug metabolism, pharmacodynamics, and tolerance to perioperative stress, resulting in higher rates of cardiovascular, respiratory, and cognitive complications compared with younger adults.ResultsOlder patients require careful dose adjustments due to reduced drug clearance and increased sensitivity to anesthetics. Propofol-based total intravenous anesthesia (TIVA), EEG-guided depth monitoring, and agents like etomidate or dexmedetomidine improve hemodynamic stability and reduce postoperative cognitive dysfunction (POCD) and delirium. Comprehensive preoperative evaluation—including frailty screening, cognitive and functional assessment, and medication review—helps identify high-risk patients. Postoperative vigilance is needed to manage respiratory depression, inadequate pain control, and prolonged recovery. Telemedicine has proven effective for pre-anesthetic assessment, enabling early detection of cognitive impairment and reducing time, cost, and travel burden.DiscussionPersonalized anesthesia considering frailty, comorbidities, and altered drug metabolism improves safety. Minimizing anesthetic duration, selecting safer agents, EEG guidance, and TIVA support better outcomes, while telemedicine enhances patient-centered care.ConclusionGeneral anesthesia in older adults requires tailored strategies addressing age-related changes and increased perioperative vulnerability. Individualized dosing, careful agent selection, structured preoperative assessment, postoperative monitoring, and telemedicine support can enhance safety and outcomes, highlighting key differences from younger patients and emphasizing a holistic, evidence-based perioperative approach.

17 August 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MJMichał Janiak
Michał Janiak
Katarzyna Mądra-GackowskaKatarzyna Mądra-Gackowska
Katarzyna Mądra-Gackowska
LWLidia Wydeheft
Lidia Wydeheft
Marcin GackowskiMarcin Gackowski
Marcin Gackowski
Background/Objectives: Oral small-molecule inhibitors of activated factor XI (FXIa) are intended to attenuate thrombosis with less disruption of hemostasis than established anticoagulants, but clinical outcomes have not consistently paralleled pharmacodynamic target engagement. This systematic review integrated molecular design, preclinical pharmacology, human pharmacokinetics/pharmacodynamics (PK/PD), and clinical outcomes to identify where translation is maintained or lost. Methods: The review followed PRISMA 2020 and PRISMA-S and was registered in PROSPERO (CRD420261356169). PubMed/MEDLINE, Scopus, and Web of Science Core Collection were searched from inception through 30 March 2026 and rerun on 11 August 2026, with a final publication-eligibility cut-off of 30 June 2026. Owing to heterogeneity, evidence was synthesized narratively. Results: Sixty-eight eligible reports were included, comprising seven randomized parent outcome trials and nine reports with in vivo thrombosis or bleeding experiments. In the OCEANIC-STROKE trial, ischemic stroke occurred in 6.2% with asundexian versus 8.4% with placebo (HR 0.74, 95% CI 0.65–0.84), while major bleeding was 1.9% versus 1.7% (HR 1.10, 95% CI 0.85–1.44). In OCEANIC-AF, stroke or systemic embolism occurred in 1.3% with asundexian versus 0.4% with apixaban (HR 3.79, 95% CI 2.46–5.83), despite less major bleeding (0.2% vs. 0.7%; HR 0.32, 95% CI 0.18–0.55). Conclusions: Oral small-molecule FXIa inhibition is pharmacologically coherent, but clinical benefit is indication-, comparator-, and background-therapy-dependent. PD markers confirm target engagement but are not validated efficacy surrogates; hard clinical outcomes remain decisive.